BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29

From Startup Brainstorm Cell Therapeutics

Link to Full Article:

Conference Call and Live Webcast at 8:30am Eastern Time
NEW YORK and PETACH TIKVAH, Israel, Oct. 17, 2018 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the third quarter ended September 30, 2018, and provide a corporate update, on Monday, October 29 at 8:30am Eastern Time.
Monday, October 29, 2018 @ 8:30am Eastern Time
Toll Free:
Israel Investors:
1809 212 909
Conference ID:
Replays, available through November 12, 2018
Toll Free:
Conference ID:
About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases.
The Company has developed the NurOwn® technology into a commercially viable product. NurOwn® has been already administered to over 70 patients with ALS in clinical trials conducted in the United States and in Israel. In a randomized, double blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. The Company is currently conducting a Phase 3 double blind, placebo-controlled clinical trial at multiple clinical sites throughout the US. For more information, visit the company’s website at
CONTACTSMedia:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: (646)
Investors:Michael RiceLifeSci Advisors, LLCPhone:

BrainStorm Cell Therapeutics Inc.

Please visit their site for more information: Brainstorm Cell

All,Biotechnology,Healthcare News,Startup News
2018-10-18 06:04:04